Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLFS NASDAQ:NPCE NASDAQ:PLSE NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$22.26-0.8%$22.09$19.10▼$29.55$1.07B1.79505,944 shs407,093 shsNPCENeuroPace$9.07-4.5%$11.89$5.45▼$18.98$311.59M1.93335,577 shs177,803 shsPLSEPulse Biosciences$14.87-2.0%$16.07$13.50▼$25.00$1.02B1.56162,242 shs95,488 shsTNDMTandem Diabetes Care$15.44-4.4%$19.00$14.31▼$47.60$1.08B1.481.75 million shs1.46 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions+4.86%+6.70%+5.10%-9.48%-1.36%NPCENeuroPace+1.60%+4.28%-10.12%-15.56%+12.29%PLSEPulse Biosciences+0.07%-3.50%-2.07%-21.28%-13.07%TNDMTandem Diabetes Care+5.49%+2.54%-20.13%-8.60%-63.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLFSBioLife Solutions2.564 of 5 stars3.51.00.00.02.92.50.6NPCENeuroPace2.8203 of 5 stars3.53.00.00.00.04.20.6PLSEPulse Biosciences3.4936 of 5 stars3.50.00.04.20.04.20.0TNDMTandem Diabetes Care4.3163 of 5 stars4.21.00.04.94.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLFSBioLife Solutions 3.00Buy$31.0039.26% UpsideNPCENeuroPace 3.00Buy$17.0087.43% UpsidePLSEPulse Biosciences 3.00Buy$22.0047.95% UpsideTNDMTandem Diabetes Care 2.33Hold$32.71111.88% UpsideCurrent Analyst Ratings BreakdownLatest NPCE, PLSE, BLFS, and TNDM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025BLFSBioLife SolutionsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$30.007/9/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Sell$24.00 ➝ $14.007/7/2025PLSEPulse BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$22.006/16/2025TNDMTandem Diabetes CareTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$24.005/28/2025NPCENeuroPaceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.005/22/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $24.005/14/2025NPCENeuroPaceJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $16.005/14/2025NPCENeuroPaceCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$17.00 ➝ $17.005/13/2025BLFSBioLife SolutionsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/1/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$58.00 ➝ $59.005/1/2025TNDMTandem Diabetes CareStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $31.00(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLFSBioLife Solutions$82.25M12.94$0.12 per share183.25$7.52 per share2.96NPCENeuroPace$79.91M3.72N/AN/A$0.27 per share33.59PLSEPulse BiosciencesN/AN/AN/AN/A$1.87 per shareN/ATNDMTandem Diabetes Care$940.20M1.09N/AN/A$4.01 per share3.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLFSBioLife Solutions-$20.18M-$0.29N/AN/AN/A-11.81%-0.66%-0.58%8/14/2025 (Estimated)NPCENeuroPace-$27.14M-$0.84N/AN/AN/A-29.42%-190.84%-25.08%8/12/2025 (Estimated)PLSEPulse Biosciences-$53.58MN/A0.00∞N/AN/A-68.44%-58.17%8/14/2025 (Estimated)TNDMTandem Diabetes Care-$96.03M-$2.78N/AN/AN/A-18.71%-57.33%-13.48%8/6/2025 (Confirmed)Latest NPCE, PLSE, BLFS, and TNDM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025BLFSBioLife Solutions-$0.02N/AN/AN/AN/AN/A8/14/2025Q2 2025PLSEPulse Biosciences-$0.26N/AN/AN/AN/AN/A8/12/2025Q2 2025NPCENeuroPace-$0.24N/AN/AN/A$23.08 millionN/A8/6/2025Q2 2025TNDMTandem Diabetes Care-$0.40N/AN/AN/A$238.39 millionN/A5/13/2025Q1 2025NPCENeuroPace-$0.26-$0.21+$0.05-$0.21$21.85 million$22.52 million5/8/2025Q1 2025BLFSBioLife Solutions-$0.03$0.04+$0.07-$0.01$22.22 million$23.94 million5/8/2025Q1 2025PLSEPulse BiosciencesN/A-$0.25N/A-$0.25N/AN/A4/30/2025Q1 2025TNDMTandem Diabetes Care-$0.60-$0.67-$0.07-$1.97$220.19 million$234.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLFSBioLife SolutionsN/AN/AN/AN/AN/ANPCENeuroPaceN/AN/AN/AN/AN/APLSEPulse BiosciencesN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLFSBioLife Solutions0.014.733.74NPCENeuroPace2.466.635.70PLSEPulse BiosciencesN/A15.5815.58TNDMTandem Diabetes Care1.992.301.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLFSBioLife Solutions93.24%NPCENeuroPace78.83%PLSEPulse Biosciences76.95%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipBLFSBioLife Solutions2.20%NPCENeuroPace20.50%PLSEPulse Biosciences71.50%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLFSBioLife Solutions44047.83 million46.78 millionOptionableNPCENeuroPace17032.80 million26.08 millionOptionablePLSEPulse Biosciences14067.27 million19.17 millionOptionableTNDMTandem Diabetes Care2,65066.61 million65.34 millionOptionableNPCE, PLSE, BLFS, and TNDM HeadlinesRecent News About These Companies1492 Capital Management LLC Makes New $430,000 Investment in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)July 24 at 7:03 AM | marketbeat.comEnvestnet Asset Management Inc. Buys 64,467 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)July 24 at 3:25 AM | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Purchased by Cerity Partners LLCJuly 22 at 5:50 AM | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Hits New 12-Month Low - Time to Sell?July 21 at 6:32 PM | marketbeat.comDown 27.0% in 4 Weeks, Here's Why You Should You Buy the Dip in Tandem Diabetes Care (TNDM)July 21 at 10:36 AM | zacks.comGW&K Investment Management LLC Purchases 740,499 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)July 21 at 9:26 AM | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of "Hold" by AnalystsJuly 20, 2025 | marketbeat.comHussman Strategic Advisors Inc. Makes New $1.21 Million Investment in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)July 19, 2025 | marketbeat.comFY2025 Earnings Estimate for TNDM Issued By Leerink PartnrsJuly 18, 2025 | americanbankingnews.comTandem Diabetes Care's SWOT analysis: stock faces headwinds amid market shiftsJuly 17, 2025 | investing.comWhat is Leerink Partnrs' Estimate for TNDM FY2025 Earnings?July 16, 2025 | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Hits New 52-Week Low - Here's What HappenedJuly 15, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Bought by Stephens Investment Management Group LLCJuly 13, 2025 | marketbeat.comEarnings Forecast & History for Tandem Diabetes Care Inc (TNDM) | Price ...July 12, 2025 | investing.comTandem Diabetes stock falls after Citi downgrades to Sell on competition concernsJuly 9, 2025 | au.investing.comCiti adjusts MedTech outlook: Bullish on Haemonetics, bearish on Tandem DiabetesJuly 9, 2025 | finance.yahoo.comTandem Diabetes Shares Drop Following Citi Downgrade Over Rising CompetitionJuly 9, 2025 | msn.comWhy Tandem Diabetes (TNDM) Shares Are Sliding TodayJuly 9, 2025 | msn.comTandem Diabetes Care (NASDAQ:TNDM) Sets New 12-Month Low - Here's WhyJuly 9, 2025 | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Given "Sell" Rating at CitigroupJuly 9, 2025 | marketbeat.comFurther weakness as Tandem Diabetes Care (NASDAQ:TNDM) drops 10.0% this week, taking five-year losses to 83%July 7, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNPCE, PLSE, BLFS, and TNDM Company DescriptionsBioLife Solutions NASDAQ:BLFS$22.26 -0.19 (-0.85%) Closing price 04:00 PM EasternExtended Trading$22.27 +0.01 (+0.04%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.NeuroPace NASDAQ:NPCE$9.07 -0.43 (-4.53%) Closing price 04:00 PM EasternExtended Trading$9.14 +0.07 (+0.77%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Pulse Biosciences NASDAQ:PLSE$14.87 -0.30 (-1.98%) Closing price 04:00 PM EasternExtended Trading$14.89 +0.02 (+0.13%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.Tandem Diabetes Care NASDAQ:TNDM$15.44 -0.71 (-4.40%) Closing price 04:00 PM EasternExtended Trading$15.68 +0.24 (+1.55%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
